Company Description
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States.
The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals.
Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, ready to drink cans, and sleep, focus, and calming aids.
It also provides veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand.
It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers.
The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019.
cbdMD, Inc. is headquartered in Charlotte, North Carolina.
| Country | United States |
| Founded | 2015 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 42 |
| CEO | T. Kennedy |
Contact Details
Address: 2101 Westinghouse Blvd, Suite A Charlotte, North Carolina 28273 United States | |
| Phone | 704 445 3060 |
| Website | cbdmd.com |
Stock Details
| Ticker Symbol | YCBD |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001644903 |
| CUSIP Number | 12482W101 |
| ISIN Number | US12482W3097 |
| Employer ID | 47-3414576 |
| SIC Code | 2844 |
Key Executives
| Name | Position |
|---|---|
| T. Kennedy | Chief Executive Officer |
| T. Kennedy | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 6, 2025 | 8-K | Current Report |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| May 20, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | SCHEDULE 13G | Filing |
| May 8, 2025 | SCHEDULE 13D | Filing |
| May 7, 2025 | 8-K | Current Report |
| May 6, 2025 | 25-NSE | Filing |
| Apr 11, 2025 | 8-K | Current Report |